HBV pgRNA induces chronic inflammation in an IL-1β-dependent manner - Takeaways - MDSpire

HBV pgRNA induces chronic inflammation in an IL-1β-dependent manner

  • By

  • Aikaterini Skeva

  • Konstantinos Marmanis

  • Maria Ntinopoulou

  • Panagiotis Liakopoulos

  • Eleni Tryfonopoulou

  • Anna Chalkidou

  • Stella Arelaki

  • Katerina Chlichlia

  • Maria Koffa

  • Akrivi Chrysanthopoulou

  • Petros Kolovos

  • Alexandra Giatromanolaki

  • Konstantinos Mimidis

  • Theocharis G. Konstantinidis

  • Maria Panopoulou

  • June 22, 2026

  • 0 min

Share

  • 1

    Chronic hepatitis B (CHB) affects approximately 250 million people globally and can lead to severe complications if untreated.

  • 2

    The study analyzed 88 CHB patients receiving nucleoside analogs, revealing that 18.1% were positive for HBV pregenomic RNA (pgRNA).

  • 3

    Transcriptomic analysis identified pathways related to platelet activation and neutrophil degranulation in HBV pgRNA-positive patients.

  • 4

    Platelets stimulated with HBV pgRNA-positive serum exhibited autophagy and increased synthesis of the peptide LL-37.

  • 5

    The study found that HBV pgRNA activates platelets, leading to a proinflammatory phenotype characterized by elevated IL-1β levels.

Original Source(s)

HBV pgRNA induces chronic inflammation in an IL-1β-dependent manner

  • by Aikaterini Skeva, Konstantinos Marmanis, Maria Ntinopoulou, Panagiotis Liakopoulos, Eleni Tryfonopoulou, Anna Chalkidou, Stella Arelaki, Katerina Chlichlia, Maria Koffa, Akrivi Chrysanthopoulou, Petros Kolovos, Alexandra Giatromanolaki, Konstantinos Mimidis, Theocharis G. Konstantinidis, Maria Panopoulou

  • June 22, 2026

Related Content

CD4 T cell phenotype after AS01-adjuvanted immunization is shaped by prior antigen or pathogen exposure

Clinical characteristics, predictive factors, and therapeutic outcomes of mycoplasma pneumoniae pneumonia with pleural effusion in children: a retrospective cohort study

Immunogenicity and protective potential of a mucosal protein-only vaccine candidate for tuberculosis